Cite
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.
MLA
Lindsay, James O., et al. “Safety and Efficacy of Autologous Haematopoietic Stem-Cell Transplantation with Low-Dose Cyclophosphamide Mobilisation and Reduced Intensity Conditioning versus Standard of Care in Refractory Crohn’s Disease (ASTIClite): An Open-Label, Multicentre, Randomised Controlled Trial.” The Lancet. Gastroenterology & Hepatology, vol. 9, no. 4, Apr. 2024, pp. 333–45. EBSCOhost, https://doi.org/10.1016/S2468-1253(23)00460-0.
APA
Lindsay, J. O., Hind, D., Swaby, L., Berntsson, H., Bradburn, M., Bannur C, U., Byrne, J., Clarke, C., Desoysa, L., Dickins, B., Din, S., Emsley, R., Foulds, G. A., Gribben, J., Hawkey, C., Irving, P. M., Kazmi, M., Lee, E., Loban, A., … Snowden, J. A. (2024). Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn’s disease (ASTIClite): an open-label, multicentre, randomised controlled trial. The Lancet. Gastroenterology & Hepatology, 9(4), 333–345. https://doi.org/10.1016/S2468-1253(23)00460-0
Chicago
Lindsay, James O, Daniel Hind, Lizzie Swaby, Hannah Berntsson, Mike Bradburn, Uday Bannur C, Jennifer Byrne, et al. 2024. “Safety and Efficacy of Autologous Haematopoietic Stem-Cell Transplantation with Low-Dose Cyclophosphamide Mobilisation and Reduced Intensity Conditioning versus Standard of Care in Refractory Crohn’s Disease (ASTIClite): An Open-Label, Multicentre, Randomised Controlled Trial.” The Lancet. Gastroenterology & Hepatology 9 (4): 333–45. doi:10.1016/S2468-1253(23)00460-0.